1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Poulsen, S.-A. Watson, A.A. Craik, D.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Struct.Biol. JSBIEM 0803 1047-8477 130 142 152 10.1006/jsbi.2000.4267 10940222 Solution structures in aqueous SDS micelles of two amyloid beta peptides of A beta(1-28) mutated at the alpha-secretase cleavage site (K16E, K16F) 2000 10.2210/pdb1bjc/pdb pdb_00001bjc 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 3286.500 AMYLOID BETA-PEPTIDE ABETA [F16], RESIDUES 1-28 K16F 1 man polymer no no DAEFRHDSGYEVHHQFLVFFAEDVGSNK DAEFRHDSGYEVHHQFLVFFAEDVGSNK A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens 32644 unidentified database_2 pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1998-11-18 1 1 2008-03-24 1 2 2011-07-13 1 3 2021-11-03 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site _struct_ref_seq_dif.details Y BNL 1998-06-23 REL REL THE STRUCTURE WAS DETERMINED FROM 2-DIMENSIONAL NMR DATA ON UNLABELLED PEPTIDE LOW ENERGY, LOW VIOLATIONS 50 15 NOESY TOCSY 5.8 1 atm 296 K REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS SDS MICELLES (100MM)/D2O, H2O BRUNGER refinement XPLOR structure solution X-PLOR 500 Bruker AMX-500 750 Bruker DRX-750 ASP 1 n 1 ASP 1 A ALA 2 n 2 ALA 2 A GLU 3 n 3 GLU 3 A PHE 4 n 4 PHE 4 A ARG 5 n 5 ARG 5 A HIS 6 n 6 HIS 6 A ASP 7 n 7 ASP 7 A SER 8 n 8 SER 8 A GLY 9 n 9 GLY 9 A TYR 10 n 10 TYR 10 A GLU 11 n 11 GLU 11 A VAL 12 n 12 VAL 12 A HIS 13 n 13 HIS 13 A HIS 14 n 14 HIS 14 A GLN 15 n 15 GLN 15 A PHE 16 n 16 PHE 16 A LEU 17 n 17 LEU 17 A VAL 18 n 18 VAL 18 A PHE 19 n 19 PHE 19 A PHE 20 n 20 PHE 20 A ALA 21 n 21 ALA 21 A GLU 22 n 22 GLU 22 A ASP 23 n 23 ASP 23 A VAL 24 n 24 VAL 24 A GLY 25 n 25 GLY 25 A SER 26 n 26 SER 26 A ASN 27 n 27 ASN 27 A LYS 28 n 28 LYS 28 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A ALA 2 60.07 60.70 1 A GLU 3 -81.31 35.88 1 A PHE 4 -154.98 13.12 1 A ARG 5 -68.31 71.95 1 A HIS 6 -177.47 -21.00 1 A GLU 11 -172.26 104.69 1 A PHE 16 -132.86 -50.39 1 A SER 26 -88.06 32.77 2 A GLU 3 -96.51 32.60 2 A PHE 4 -152.02 62.91 2 A ARG 5 -164.08 33.16 2 A HIS 6 51.16 17.43 2 A SER 8 55.82 17.06 2 A TYR 10 -65.62 -175.12 2 A GLU 11 -174.00 113.13 2 A HIS 13 67.86 -18.56 3 A GLU 3 -165.83 26.40 3 A PHE 4 -81.79 34.46 3 A HIS 6 51.26 11.97 3 A TYR 10 -70.71 -165.13 3 A GLU 11 -172.47 115.58 3 A HIS 13 -178.15 -51.64 3 A ALA 21 -55.98 -7.71 3 A ASP 23 -142.03 -34.76 3 A SER 26 56.54 14.15 4 A ARG 5 -101.34 49.56 4 A GLU 11 -171.33 100.17 4 A HIS 13 44.10 26.78 4 A HIS 14 36.89 42.54 4 A GLN 15 -69.74 13.45 4 A ASP 23 -145.07 32.67 4 A VAL 24 -136.30 -32.85 4 A SER 26 -167.18 -42.32 5 A PHE 4 -107.02 62.14 5 A ARG 5 -150.52 45.75 5 A GLU 11 173.82 122.50 5 A HIS 13 -169.26 -2.37 5 A GLN 15 -160.15 8.33 5 A SER 26 -163.79 -39.70 5 A ASN 27 -87.90 43.79 6 A ALA 2 -153.37 70.31 6 A PHE 4 -148.66 29.09 6 A HIS 6 73.73 51.84 6 A GLU 11 -170.37 104.84 6 A HIS 13 -179.33 -59.34 6 A HIS 14 -170.47 -111.49 6 A LEU 17 86.00 -27.67 6 A GLU 22 -141.83 -43.34 7 A ALA 2 -77.64 -166.46 7 A GLU 11 -172.17 103.56 7 A GLN 15 -163.02 26.76 7 A ALA 21 -66.58 13.02 7 A ASP 23 -131.70 -37.24 7 A SER 26 -155.01 70.81 7 A ASN 27 -141.67 -2.49 8 A ALA 2 56.04 72.53 8 A GLU 3 -85.40 45.58 8 A PHE 4 -165.75 18.33 8 A HIS 6 65.96 76.07 8 A ASP 7 -82.81 30.55 8 A GLU 11 -163.75 106.85 8 A HIS 13 -174.24 -22.36 8 A ASP 23 -148.79 30.71 8 A VAL 24 -132.27 -31.41 9 A HIS 6 -165.15 -64.53 9 A TYR 10 61.94 157.74 9 A GLU 11 -176.84 127.82 9 A VAL 12 -131.04 -34.10 9 A HIS 13 77.95 -53.75 9 A GLN 15 -166.48 51.57 9 A PHE 16 -133.35 -55.04 10 A ARG 5 45.22 24.18 10 A HIS 6 -173.72 9.30 10 A SER 8 44.60 20.03 10 A GLU 11 -175.25 127.04 10 A VAL 12 -97.11 -64.60 10 A HIS 13 54.64 6.35 10 A HIS 14 -78.04 -83.20 10 A VAL 24 -123.44 -51.40 10 A ASN 27 58.30 6.34 11 A GLU 3 -78.72 23.00 11 A PHE 4 -143.21 20.88 11 A GLU 11 -164.63 103.28 11 A HIS 13 78.34 -51.16 11 A HIS 14 -82.92 -153.39 11 A LEU 17 86.62 -27.99 11 A ASN 27 -138.85 -32.34 12 A ALA 2 -105.99 57.18 12 A ARG 5 -166.57 6.32 12 A ASP 7 -155.60 23.78 12 A TYR 10 39.08 -149.14 12 A HIS 13 78.51 -33.60 12 A GLN 15 -77.00 33.85 12 A VAL 24 -131.79 -44.20 12 A SER 26 -157.13 -33.68 12 A ASN 27 -140.88 41.36 13 A ALA 2 -160.35 52.84 13 A GLU 3 -88.38 34.76 13 A GLU 11 -174.43 112.74 13 A HIS 13 69.39 -2.29 13 A HIS 14 26.08 69.71 13 A ASP 23 -145.48 27.80 13 A SER 26 -163.97 69.27 14 A ALA 2 51.00 74.03 14 A ARG 5 -157.21 25.18 14 A HIS 6 -133.81 -50.35 14 A TYR 10 179.28 166.05 14 A VAL 12 -121.89 -58.01 14 A HIS 13 75.13 -49.84 14 A PHE 19 -65.19 2.72 14 A ALA 21 -147.32 -33.42 14 A SER 26 59.13 14.52 15 A ALA 2 -167.24 69.25 15 A GLU 3 -82.64 31.48 15 A ARG 5 -153.13 22.25 15 A HIS 6 -178.32 -47.40 15 A TYR 10 48.06 -173.00 15 A GLU 11 -158.41 83.43 15 A GLN 15 49.47 24.24 15 A VAL 24 -139.65 -33.17 15 A SER 26 -150.97 7.68 model building X-PLOR refinement X-PLOR phasing X-PLOR SOLUTION NMR STRUCTURE OF AMYLOID BETA[F16], RESIDUES 1-28, 15 STRUCTURES 1 Y N A LEU 17 A LEU 17 HELX_P A VAL 24 A VAL 24 1 1 8 GLYCOPROTEIN GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE A4_HUMAN UNP 1 1 P05067 MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 672 699 1BJC 1 28 P05067 A 1 1 28 1 LYS engineered mutation PHE 16 1BJC A P05067 UNP 687 16 1 P 1